Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics

Entrada Therapeutics, Inc. (TRDA): $14.00

0.86 (+6.54%)

POWR Rating

Component Grades

Momentum

B

Stability

C

Sentiment

Quality

C

Add TRDA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#21 of 381

in industry

TRDA Price/Volume Stats

Current price $14.00 52-week high $24.38
Prev. close $13.14 52-week low $6.04
Day low $13.19 Volume 54,600
Day high $14.09 Avg. volume 47,942
50-day MA $13.56 Dividend yield N/A
200-day MA $14.77 Market Cap 464.76M

TRDA Stock Price Chart Interactive Chart >


Entrada Therapeutics, Inc. (TRDA) Company Bio


Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.


TRDA Latest News Stream


Event/Time News Detail
Loading, please wait...

TRDA Latest Social Stream


Loading social stream, please wait...

View Full TRDA Social Stream

Latest TRDA News From Around the Web

Below are the latest news stories about ENTRADA THERAPEUTICS INC that investors may wish to consider to help them evaluate TRDA as an investment opportunity.

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. The fireside chat will be held on Wednesday,

Yahoo | June 6, 2023

Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates

The analysts covering Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) delivered a dose of negativity to shareholders today...

Yahoo | May 15, 2023

Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a good week for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, because the company has just...

Yahoo | May 13, 2023

Entrada Therapeutics Reports First Quarter 2023 Financial Results

- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent busines

Yahoo | May 10, 2023

We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | April 30, 2023

Read More 'TRDA' Stories Here

TRDA Price Returns

1-mo 20.79%
3-mo 16.67%
6-mo -26.59%
1-year 76.54%
3-year N/A
5-year N/A
YTD 3.55%
2022 -21.03%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!